Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Trevena, Inc. (Nasdaq: TRVN) announced the U.S. approval of OLINVYK™ for acute pain management, marking a significant milestone in 2020 amid COVID-19 challenges. The company reported a net loss of $29.4 million for the year, up from $24.9 million in 2019, attributed to preparation for OLINVYK's launch. With $109.4 million in cash, Trevena is positioned to fund operations through 2022. The company also highlighted progress in its pipeline, including TRV027 for COVID-19 and TRV045 for epilepsy and neuropathic pain, with key developments expected in 2021.
Trevena, Inc. (Nasdaq: TRVN) announced it will release its fourth quarter and full year 2020 financial results on March 9, 2021, prior to market opening. A conference call is scheduled for 8:00 a.m. ET the same day, featuring key executives discussing the results. Dr. Gregory Hammer from Stanford University will also speak on OLINVYK™, Trevena's approved drug for acute pain management. Additionally, Carrie Bourdow, CEO, will participate in a panel on reimbursement considerations during the H.C. Wainwright Global Life Sciences Virtual Conference.
Trevena, Inc. (Nasdaq: TRVN) has announced its participation in two virtual investor conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring one-on-one investor meetings. The second event is the Oppenheimer 31st Annual Healthcare Conference on March 16, which will include a corporate presentation at 3:50 p.m. ET followed by one-on-one meetings. Trevena is focused on developing novel CNS medicines, including its approved product OLINVYK and several investigational candidates.
On February 22, 2021, Trevena, Inc. (TRVN) announced a corporate update presentation at the 10th Annual SVB Leerink Global Healthcare Conference.
The event is scheduled for February 26, 2021, at 8:40 a.m. EST, featuring Bob Yoder, Senior VP and Chief Commercial Officer.
The webcast will be accessible on Trevena's Investors section. The company focuses on CNS disorders, with one approved product, OLINVYK™, and several investigational drug candidates, including TRV250 for migraine and TRV734 for opioid use disorder.
Trevena, Inc. (Nasdaq: TRVN) reported low incidences of opioid-induced respiratory depression (OIRD) with OLINVYK in a Phase 3 safety study. The analysis showed no significant differences in OIRD rates among elderly (10.8%) vs. younger patients (15.1%), and between obese (14.0%) and non-obese patients (13.4%). The overall OIRD incidence was 13.7%, with none requiring naloxone for reversal. This study underlines OLINVYK's potential for safer opioid pain management, particularly for high-risk patients. OLINVYK was approved by the FDA in August 2020 for acute pain management.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on CNS disorders, announced its participation in two virtual investor conferences. The LifeSci Partners Healthcare Corporate Access Event is on January 8, 2021, at 2:00 p.m. ET, featuring a panel discussion led by President & CEO Carrie Bourdow. The H.C. Wainwright BioConnect Conference will occur on January 11, 2021, at 6:00 a.m. ET, with a fireside chat presentation by Bourdow and SVP Bob Yoder. Webcasts for both events are available on Trevena's website.
Trevena, Inc. (Nasdaq: TRVN) announced updates on the U.S. commercial launch of its product OLINVYK (oliceridine) for acute pain management. The drug is now available through major wholesalers, and the company is actively engaging healthcare professionals to facilitate formulary inclusion.
The company aims for 100 formulary acceptances in 2021 while managing customer outreach in the context of COVID-19. Additionally, Trevena is on track for key milestones in its pipeline, including reporting topline data for its COVID-19 trial of TRV027 this quarter and submitting an IND filing for TRV045 in 1H 2021.
Trevena, Inc. (Nasdaq: TRVN) recently presented research on TRV045 at the ACNP's 59th Annual Meeting, focusing on its potential use in treating CNS disorders such as epilepsy and neuropathic pain. TRV045 selectively targets the S1P1 receptor without causing lymphopenia, demonstrating comparable efficacy to known treatments in animal models. The company is collaborating with the NIH for further evaluation and is on track to file an IND in the first half of 2021 for TRV045.
Trevena, Inc. (Nasdaq: TRVN) announced significant findings from a study on OLINVYK (oliceridine), demonstrating a 2-3x better gastrointestinal tolerability compared to IV morphine post-surgery. In orthopedic and plastic surgery trials, patients showed a higher prevalence of 'complete GI response' with OLINVYK, achieving 76.3% versus 32.9% for morphine. These results suggest OLINVYK could improve recovery by reducing post-operative nausea and vomiting, a common complication affecting patient outcomes.
Trevena, Inc. (Nasdaq: TRVN) has announced its participation in two healthcare conferences this November. The Guggenheim Healthcare Talks will take place on November 16, featuring one-on-one meetings with management, including CEO Carrie Bourdow. Following that, Trevena will present at the Stifel Virtual Healthcare Conference on November 18 from 4:40 to 5:10 PM ET. Trevena focuses on developing innovative treatments for patients with CNS disorders, with products like OLINVYK™ (oliceridine) already available.
FAQ
What is the current stock price of TREVENA (TRVN)?
What is the market cap of TREVENA (TRVN)?
What is Trevena, Inc.?
What is OLINVYK®?
What recent developments has Trevena announced?
What is TRV045?
How is Trevena's financial performance?
What types of products does Trevena develop?
Are Trevena's products FDA approved?
What partnerships does Trevena have?
Where can I find more information about Trevena’s research?
What are the primary focus areas of Trevena's research?
